Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CLCO -8%, ZS -5%, CAN -1.8%, BNS -1.6%, ESLT -1.3%
Other news:
- SNES -38.8% (launches Evolve Soft Bait)
- ARGX -10.7% (reports topline results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia; Study did not meet primary or secondary endpoints)
- SLRN -8% (provides Izokibep update)
- TRMD -3.8% (10% owner disclosed plans to sell approx. 2.8 mln shares)
- PRAX -3.3% (Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings) OBIO -2.9% (amended lock-up agreement with certain investors)
- ALDX -2.3% (receives complete response letter from FDA for Reproxalap)
- APLM -1.8% (Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer)
- NARI -1.6% (first patient enrolled in PEERLESS II trial)
- SDA -1.1% (stock offering)
Analyst comments:
- AXL -4.3% (downgraded to Underperform from Neutral at BofA Securities)
- EW -2.2% (downgraded to Underperform from Peer Perform at Wolfe Research)
- BAH -1.1% (downgraded to Equal Weight from Overweight at Wells Fargo)